Abstract: Disclosed herein are uses of a polypeptide comprising NIMoEsh to treat a disease or condition associated with acute myocardial infarction (AMI) in a subject in need thereof, of a polypeptide comprising NIMoEsh to restore heart function after AMI in a subject in need thereof, of a polypeptide comprising NIMoEsh to reduce or prevent AMI-induced heart function loss in a subject in need thereof, of a polypeptide comprising NIMoEsh to reduce AMI-induced heart tissue infarct in a subject in need thereof, and of a polypeptide comprising NIMoEsh to protect cardiomyocytes against AMI-induced function loss in a subject in need thereof. Disclosed also herein are methods by which such treating, restoring, reducing or preventing, reducing, and/or protecting may be done, and a polypeptide comprising NIMoEsh for use in such treating, restoring, reducing or preventing, reducing, and/or protecting.

Abstract: Isolated polypeptides are disclosed herein, the isolated polypeptides comprising at least 90% identity to any one of: SEQ ID NO:1; SEQ ID NO:2; or SEQ ID NO:3, wherein the isolated polypeptide inhibits an interaction between palmitoyl acyl transferase zinc-finger DHHC type containing 17 (z D17) and c-jun N-terminal kinase (JNK). The polypeptides may be conjugated to a delivery and targeting moiety, such as the cell-membrane transduction domain of the HIV-1 Tat protein. There are also provided methods for treating a disease associated with cytotoxicity or excitotoxicity.

Abstract: Isolated polypeptides are disclosed herein, the isolated polypeptides comprising at least 90% identity to any one of: SEQ ID NO:1; SEQ ID NO:2; or SEQ ID NO:3, wherein the isolated polypeptide inhibits an interaction between palmitoyl acyl transferase zinc-finger DHHC type containing 17 (z D17) and c-jun N-terminal kinase (JNK). The polypeptides may be conjugated to a delivery and targeting moiety, such as the cell-membrane transduction domain of the HIV-1 Tat protein. There are also provided methods for treating a disease associated with cytotoxicity or excitotoxicity.

Abstract: The present invention is directed to a method of modulating inflammation within an immune privileged site in an animal by introducing an effective amount of a Fas ligand fragment comprising the extracellular domain of a full length Fas ligand, a derivative thereof, or a nucleic acid encoding the Fas ligand fragment, behind the blood-tissue barrier of the immune privileged site. In one embodiment the invention pertains to methods of modulating inflammation in the central nervous system generally, at specific lesions in the central nervous system, anterior chamber of the eye, testis, placenta and other immune privileged sites in a mammal. The FasL fragments used in the method of the present invention contain the extracellular domain of FasL and are soluble. The method of the present invention comprises the step of directly administering the FasL fragment, or derivative thereof, or a composition comprising the FasL fragment, or derivative thereof, behind the blood-tissue barrier of the immune privileged site.

Abstract: A self-steering platform system incorporates at least three and preferably four microphones circumferentially spaced about the platform which is mounted for movement preferably around two mutually perpendicular axes. A sound source is selected and separate audio signals from the microphones are analyzed by a control which based on differences between the signals from the microphones emanating from the selected source determines the location of the selected source. The orientation of the platform is then adjusted by the control relative to the selected sound source. The present invention is particularly useful for mounting a shotgun or parabolic microphone to enhance sound from a selected source.